Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Enliven Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $46.85, Enliven Therapeutics, Inc. trades at 4.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -16.9%, return on invested capital of -15.4% and a free cash flow yield of -1.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 45.95. Over the past 52 weeks the share price ranged from $14.79 to $62.32, with a beta of 0.24.
Enliven Therapeutics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Enliven Therapeutics, Inc. (ELVN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 26.3% / 30% · Interest income / Revenue 835300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 26.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 835300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 26.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 835300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.0% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 835300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.6% / 33.33% · (Cash+Recv) / Total Assets 98.6% / 33.33% · Interest income / Revenue 835300000.0% / 5% | Fail |
No. As of September 2026, Enliven Therapeutics, Inc. (ELVN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Enliven Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 835300000.0% of each dividend: Enliven Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.